In this retrospective biomarker study, we developed a novel methylation marker panel comprising Vimentin/POU4F2 for detecting BC, achieving an AUC of 0.935, with sensitivity, specificity, and accuracy of 86.44%, 96.08% and 92.55% for diagnosing BC (Fig. 2). The gene discussed is VIM; the disease is breast cancer.